Aprea Therapeutics (APRE)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	26.29 mm	26.29 mm	26.29 mm	26.29 mm	26.29 mm	26.29 mm
Cash burn (monthly)	814.93 k	(no burn)	1.37 mm	1.23 mm	822.77 k	1.15 mm
Cash used (since last report)	4.14 mm	n/a	6.94 mm	6.25 mm	4.18 mm	5.84 mm
Cash remaining	22.15 mm	n/a	19.35 mm	20.04 mm	22.11 mm	20.45 mm
Runway (months of cash)	27.2	n/a	14.2	16.3	26.9	17.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

APRE institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	24	30	-20.0%
Opened positions	1	7	-85.7%
Closed positions	7	2	+250.0%
Increased positions	5	5	–
Reduced positions	3	3	–

13F shares	Current	Prev Q	Change
Total value	5.51 bn	8.49 bn	-35.1%
Total shares	7.11 mm	7.20 mm	-1.2%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
HealthCap VII	2.37 mm	$1.59 mm	0.0%
KDev Investments AB	1.78 mm	$8.76 mm	0.0%
5AM Ventures IV	619.16 k	$4.55 mm	0.0%
AIGH Capital Management	539.30 k	$1.48 bn	0.0%
Hirschman Orin	349.30 k	$0.00	0.0%
Sio Capital Management	276.60 k	$760.66 mm	0.0%
Sphera Funds Management	270.00 k	$742.50 mm	0.0%
Nantahala Capital Management	205.76 k	$565.84 mm	0.0%
Vanguard	173.84 k	$478.07 mm	+50.1%
DAFNA Capital Management	137.17 k	$377.23 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Altium Capital Management	0.00	-137.20 k	EXIT
Vanguard	173.84 k	+58.00 k	+50.1%
Susquehanna International	0.00	-10.12 k	EXIT
BlackRock	8.50 k	+8.50 k	NEW
BLK BlackRock	0.00	-8.50 k	EXIT
Dimensional Fund Advisors	17.06 k	+5.99 k	+54.1%
RY Royal Bank of Canada	0.00	-5.69 k	EXIT
Geode Capital Management	40.07 k	+4.39 k	+12.3%
MS Morgan Stanley	34.21 k	+4.39 k	+14.7%
Tower Research Capital	1.32 k	-1.42 k	-51.8%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

APRE insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
23 Oct 24	Oren Gilad	Common Stock	Buy	Acquire P	No	No	3.915	500	1.96 k	333,395
18 Oct 24	Marc Duey	Common Stock	Sell	Dispose S	No	No	4.578	6,462	29.58 k	233,651
16 Oct 24	Marc Duey	Common Stock	Buy	Acquire P	No	No	4.39	30,000	131.70 k	240,113
15 Oct 24	Oren Gilad	Common Stock	Buy	Acquire P	No	No	2.9	250	725.00	332,895
14 Oct 24	Marc Duey	Common Stock	Buy	Acquire P	No	No	2.58	190	490.20	210,113

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target

15 Jan 25

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 price target.

HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target

17 Dec 24

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 price target.

Aprea Therapeutics Announces Twice Daily Dosing Of Patients On ABOYA-119 Clinical Trial Of ATRN-119

11 Dec 24

Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea's experimental drug, ATRN-119, over a 24-hour daily cycleNew regimen potentially optimizes clinical

Press releases

From Benzinga Pro

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

5 Feb 25

DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

11 Dec 24